The use of the hypomethylating agent azacytidine in VEXAS syndrome has been also suggested as an effective treatment strategy, especially in patients with concomitant MDS, those without aplastic bone marrow and patients with a concomitant DNMT3A mutation. This evidence concerns the gene DNMT3A and VEXAS syndrome.